DDInter350 DDInter821
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and gastrotoxicity. Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies involved non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and liver transplantation in refractory cases. Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment of genetic disorders.
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Chlorambucil {u} (Compound) binds {v} (Gene) GSTP1
GSTP1 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Chlorambucil {u} (Compound) downregulates {v} (Gene) MYC
MYC {u} (Gene) is downregulated by {v} (Compound) Flucytosine
Flucytosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Chlorambucil {u} (Compound) causes {v} (Side Effect) Anorexia
Anorexia {u} (Side Effect) is caused by {v} (Compound) Flucytosine
Flucytosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Chlorambucil {u} (Compound) downregulates {v} (Gene) MYC
MYC {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Givosiran
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Givosiran
Chlorambucil {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Givosiran
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Chlorambucil (Compound) binds GSTP1 (Gene) and GSTP1 (Gene) is bound by Oxaliplatin (Compound) and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Chlorambucil (Compound) downregulates MYC (Gene) and MYC (Gene) is downregulated by Flucytosine (Compound) and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Chlorambucil (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Flucytosine (Compound) and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Chlorambucil (Compound) downregulates MYC (Gene) and MYC (Gene) is upregulated by Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Givosiran
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a minor interaction that can limit clinical effects when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Givosiran
Chlorambucil (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Givosiran